ASPG and acute lymphoblastic leukemia: Clinically available L-asparaginase preparations fulfil the features mentioned above, and hence tend to elicit production of anti-asparaginase antibodies from the human immune system, resulting in clinical hypersensitivity reactions or subclinical inactivation of L-asparaginases during treatment in ALL patients (14).